Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Valsartan Amlodipine Tablets, which will enhance its product offerings in the antihypertensive market [1] Group 1: Drug Registration Details - The drug is named Valsartan Amlodipine Tablets (I) and is in tablet form, with each tablet containing 80mg of Valsartan and 5mg of Amlodipine [1] - The approval number for the drug is Guo Yao Zhun Zi H20255570, classified as a Class 4 chemical drug [1] Group 2: Indication and Market Impact - The drug is indicated for the treatment of primary hypertension, specifically for patients whose blood pressure cannot be adequately controlled with monotherapy [1] - The acquisition of this drug registration certificate will further enrich the company's antihypertensive product line and enhance its market competitiveness in the hypertension sector [1]